Tris Pharma: Tris Pharma starts two Phase III registrational trials for pain therapy

The two-Phase III studies will evaluate the company's dual-NMR agonist, cebranopadol, as treatment for moderate-to-severe acute pain. The post Tris Pharma starts two Phase III registrational trials for pain therapy appeared first on Clinical Trials Arena.